Lacedor

Morphine Hydrochloride Trihydrate, the active ingredient in Lacedor, is an opioid analgesic presented as a sterile injectable solution for epidural, intramuscular, and intrathecal use. It is employed to treat severe acute or chronic pain, including postoperative and cancer‑related pain, in adult patients.

GNH USA supplies Lacedor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with full regulatory compliance and quality assurance.

Lacedor, containing morphine, is indicated for pain conditions managed through the opioid pathway.

Severe pain: provides potent analgesia for intense acute or chronic pain. Postoperative pain: controls pain following surgical procedures. Cancer pain: alleviates malignant disease‑related pain.

Adverse reactions may range from mild to life‑threatening and should be monitored closely.

Common Side Effects: - Nausea and vomiting - Constipation - Drowsiness or sedation - Dizziness or light‑headedness - Pruritus (itching) - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Anaphylactic or severe allergic reaction - Adrenal insufficiency - Urinary retention - Seizures

Careful assessment and monitoring are essential when using this opioid analgesic.

Assess pain level before initiating therapy: determine severity and underlying cause. Monitor respiratory function: watch for signs of depression, especially after dose changes. Adjust dose in renal or hepatic impairment: reduced clearance may increase risk. Avoid concurrent central nervous system depressants: increased sedation and respiratory risk. Use with caution in elderly patients: heightened sensitivity to opioid effects. Store at ambient temperature: keep in original container, protect from moisture and light.

Morphine may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Other opioids or strong analgesics: additive respiratory depression. - Central nervous system depressants (e.g., benzodiazepines, barbiturates): heightened sedation. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may increase morphine levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: can enhance hypotensive effect.